… it is an important indication of disease relapse, graft rejection … reflect the risk of relapse in
chronic myeloid leukemia (CML). … of the donor's cells in order to assess the chimerism status (…

… The aims of this study were (1) to measure the degree of donor chimaerism and its relevance
prior to DLI; (2) to monitor changes in the chimaeric profile during the pancytopenic phase …

… complete donor myeloid chimerism by post-transplantation day +… lymphocyte chimerism on
disease progression. T lymphocyte … chimerism was a stronger predictor of relapse and overall …

… best predictor of relapse after SCT in patients with aggressive … cells) or full chimerism (more
than 95% donor cells). Samples … For event free survival, the event analyzed was relapse or …

… alleles had better 2-year disease-free survival (85%) than … acute leukemias or chronic
myeloid malignancies 27, 28, 29. … the minimum percentages of donor chimerism in this period. …

… Assessing a possible association between chimerism and disease-free survival (… Relapse
of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor …

… the impact of several other disease- and treatment-related … was associated with shorter
progression-free survival (PFS) (… the post-transplantation period is the analysis of the donor …

… and T-cell donor chimerism 50 days after transplantation and … risk of disease relapse and
a reduction in relapse-free survival [8]. … predictor of full donor status at day 50. Recipient/…

… malignancies, especially acute myeloid leukaemia (AML) and … neutrophil recovery with
donor chimaerism was achieved … an indication to transplant but no available matched donor. …

… than 80% of donor origin in mice tested 70 to 150 days post-… Body weight loss can be a
sensitive indicator of GVHD." … , the probability of relapse, survival, and disease-free survival is …